echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Infection > 336 million US dollars to help "broad-spectrum" new coronavirus neutralizing antibodies enter the key clinical...

    336 million US dollars to help "broad-spectrum" new coronavirus neutralizing antibodies enter the key clinical...

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Adagio Therapeutics announced today that it has completed a $336 million Series C financing led by RA Capital Management.


    ADG20 may affect virus replication and related diseases through a variety of mechanisms of action, including directly blocking virus entry into host cells (neutralization) and mediated by Fc receptors (Fc receptors are receptors that bind to the Fc part of immunoglobulin) The immune effector activity eliminates infected host cells.


    Adagio has initiated a phase 1 clinical study in healthy volunteers and is conducting a pivotal phase 1/2/3 clinical trial in high-risk patients with mild or moderate COVID-19.


    Reference materials:

    Reference materials:

    [1] Adagio Therapeutics Announces $336 Million Series CFinancing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19.


    [1] Adagio Therapeutics Announces $336 Million Series CFinancing to Support Rapid Advancement of Novel ADG20 Antibody for the Treatment and Prevention of COVID-19.


    [2] Adagio Therapeutics Announces Dosing of First Patient inPhase 1 Trial of ADG20, its Lead Monoclonal Antibody Candidate for the Treatment and Prevention of COVID-19.


    [3] Evaluation of ADG20 for the Treatment of Mild orModerate COVID-19-Full Text View-ClinicalTrials.


    Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.


    ▽ attention [drug Mingkang Germany ] micro-channel public number

    [Medical attention Mingkang Germany ] ] micro-channel public number

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.